logo-loader
viewAnima Biotech

Anima in talks with 'over ten companies' to use its translation control therapeutics platform.

Anima Biotech CEO Yochi Slonim sat down with Proactive Investors at the BIO CEO & Investor Conference in New York. 

Israel based Anima Biotech is pioneering translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against "hard and undruggable" targets.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tiziana Life Sciences: Dr Weiner announces 'completely novel' approach to...

Harvard Medical School's Dr Howard Weiner, who's also chairman of Tiziana Life Sciences' (LON:TILS)(NASDAQ:TLSA) scientific advisory board, speaks to Proactive London's Andrew Scott after winning a competitive research grant from the NIH (National Institutes of Health) to investigate the drug's...

51 minutes ago

2 min read